DEPREXIS^® BEI DEPRESSION:

Fachkreise | Zulassung neuer Erstlinientherapie beim Pankreaskarzinom

Digitale Innovationen in der Pflege: Servier lobt „i-care-Award“ 2024 aus

FDA and EMA Accept Vorasidenib Regulatory Submissions for Marketing Approval of Vorasidenib for the Treatment of IDH-mutant Diffuse Glioma

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition